Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy significantly decreased the risk of breast cancer recurrence by 25% compared to standard adjuvant ET alone for people with hormone receptor-positive, human epidermal growth factor receptor 2-negative high risk early breast cancer (HR: 0.747; 95% CI: 0.598, 0.932; p = 0.0096).
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe